TD Cowen started coverage on shares of Rapport Therapeutics (NASDAQ:RAPP – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating on the stock.
Other analysts also recently issued reports about the stock. Stifel Nicolaus started coverage on shares of Rapport Therapeutics in a report on Tuesday. They issued a buy rating and a $35.00 price objective on the stock. Jefferies Financial Group started coverage on shares of Rapport Therapeutics in a report on Tuesday. They issued a buy rating and a $35.00 price objective on the stock.
Check Out Our Latest Stock Report on Rapport Therapeutics
Rapport Therapeutics Stock Performance
Featured Articles
- Five stocks we like better than Rapport Therapeutics
- Ride Out The Recession With These Dividend Kings
- RXO Shares Surge Following New Acquisition Deal
- How to Invest in Small Cap Stocks
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- What is Put Option Volume?
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
